Bladder transitional cell carcinoma
RecruitingStudy Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations
Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations
- Disease:Bladder transitional cell carcinoma
- Substances:ErdafitinibMitomycin+1
France- Participants:18–64 years · 65+ years
- Substances:Erdafitinib
- Sponsor:Janssen Cilag International







